Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| MK-5592-091 | Other Identifier | Merck protocol number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will examine the safety and efficacy of posaconazole in general use in Korea.
Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| All Participants | All participants treated with posaconazole oral suspension during the pre-specified surveillance period. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Posaconazole oral suspension 40 mg/mL | Drug | Posaconazole oral suspension prescribed according to the current local label |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants with Serious Adverse Experiences | During treatment and for 30 days following cessation of treatment | |
| Number of participants with drug-related adverse experiences | During treatment and for 30 days following cessation of treatment | |
| Number of participants with unexpected drug-related adverse experiences | During treatment and for 30 days following cessation of treatment | |
| Number of participants with Non-Serious Adverse Experiences | During treatment and for 30 days following cessation of treatment | |
| Number of Participants with Responses of Improved, Not Improved, and Worsened | After at least 14 days of treatment |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Participants enrolled will be all who are treated with posaconazole oral suspension per the current local label by participating investigators during the pre-specified surveillance period.
| ID | Term |
|---|---|
| D009181 | Mycoses |
| ID | Term |
|---|---|
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| C101425 | posaconazole |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided